Boehringer Ingelheim Websites
Page Tools

Our Financial Success

Boehringer Ingelheim Group of companies

In 2009, the Boehringer Ingelheim group of companies maintained its successful course again, growing faster than the pharmaceutical market for the tenth successive year.

 

Amounts in millions of EUR,
unless otherwise indicated
2009 2008 Change
Net sales 12,721 11,595 +10 %
Net sales by region      
Europe 31% 33 %  
Americas 49% 48 %  
Asia, Australasia, Africa 20% 19 %  
Net sales by business area      
Human Pharmaceuticals 95% 96 %  
Animal Health 5% 4 %  
Research and Development 2,215 2,109 +5 %
Personnel costs 3,221 3,004 +7 %
Average number of employees* 41,534 41,300 +1 %
Operating income 2,239 1,980 +13 %
Operating income as % of sales 17.6% 17.1 %  
Income after taxes 1,764 1,428 +24 %
Income after taxes as % of sales 13.9% 12.3 %  
Shareholders' equity 5,901 4,703 +25 %
Return on shareholders' equity 37.4% 42.2 %  
Cash Flow 2,409 1,997 +21 %
Investments in tangible assets 630 665 -5 %
Depreciation of tangible assets 470 453 +4 %
Amounts in millions of EUR, unless otherwise indicated